Pharmacokinetics and dosimetry of 188Re-pharmaceuticals

Compartmental and dosimetric studies of anti-CD20 labeled with 188Re

“…Techniques for radiolabeling anti-CD20 have been developed with 188 Re [6,7] to evaluate the clinical use of this radionuclide in particular. The radionuclides with properties more suitable for RIT are 188 Re, 90 Y e 131 I, while 177 Lu and 90 Y are used in therapy with peptides receptor (PRRT).…”

Synthesis and biological evaluation of 99mTc tricarbonyl complex of O,O′‐diethylethylenediamine‐N,N′‐di‐3‐propanoate as potential tumour diagnostic agent

“…[15][16][17] Rhenium-188 was early recognized as one of the most attractive radionuclides for therapy as it decays through the emission of a high-energy β-particle (E βmax = 2.1 MeV, t 1/2 = 16.9 h) with an associated γ-emission (155 keV) that can be utilized for imaging purposes. [18] [20] In the present paper, we report the synthesis of a Tc(I) tricarbonyl precursor was optimized to obtain a radiolabelled complex with high specific activity and high stability. Physicochemical characteristics like size, charge, protein binding and lipophilicity that affect the pharmacokinetic and pharmacodynamic behaviour of the complex were investigated.…”

Preclinical Evaluation of 177Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor–Overexpressing Tumors

“…Therefore, continuous research for the development of new receptor-based radiopharmaceuticals is ongoing. [13][14][15][16] 177 Lu (T1/2 ¼ 6.7 days, Ec ¼ 0.208 MeV, Ebmax ¼ 0.497 MeV, max tissue penetration ¼ 2.0 mm) is being strongly considered for RIT mainly because of the convenient energy of its beta particles and the ability to form stable complexes with macrocyclics and acyclics ligand. 4,17 Its half-life is appropriate for preparation, transport, and successful delivery of therapeutic doses to the tumor by radioimmunoconjugates such as mAbs.…”